EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Current Status and Prospects of Viral Vector-Based Gene Therapy to Treat Kidney Diseases

Louise Medaer iD, Koenraad Veys iD, Rik Gijsbers iD

Human Gene Therapy · 01.03.2024 · 35 (5-6) · 139-150

DOI: 10.1089/hum.2023.184 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Human Gene Therapy, erschienen am 01.03.2024. Verfasst von Louise Medaer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Virology and Gene Therapy, Department of Pharmacological and Pharmaceutical Sciences, Faculty of Medicine. Hauptthemen laut MEDLINE: Quality of Life, Kidney Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 92 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inherited kidney diseases are among the leading causes of chronic kidney disease, reducing the quality of life and resulting in substantial socioeconomic impact. The advent of early genetic testing and the growing understanding of the molecular basis and pathophysiology of these disorders have opened avenues for novel treatment strategies. Viral vector-based gene therapies have evolved from experimental treatments for rare diseases to potent platforms that carry the intrinsic potential to provide a cure with a single application. Several gene therapy products have reached the market, and the numbers are only expected to increase. Still, none target inherited kidney diseases. Gene transfer to the kidney has lagged when compared to other tissue-directed therapies such as hepatic, neuromuscular, and ocular tissues. Systemic delivery of genetic information to tackle kidney disease is challenging. The pharma industry is taking steps to take on kidney disease and to translate the current research into the therapeutic arena. In this review, we provide an overview of the current viral vector-based approaches and their potential. We discuss advances in platforms and injection routes that have been explored to enhance gene delivery toward kidney cells in animal models, and how these can fuel the development of viable gene therapy products for humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeKidney DiseasesAnimalsHumansGenetic TherapyGene Transfer TechniquesGenetic Vectors

Stichwörter der Autor:innen

gene therapykidney diseaseviral vectors

Autor:innen und Institutionen

  • Laboratory of Molecular Virology and Gene Therapy, Department of Pharmacological and Pharmaceutical Sciences, Faculty of Medicine.
  • Laboratory of Paediatric Nephrology, Department of Development and Regeneration, Faculty of Medicine.
  • Leuven Viral Vector Core, Faculty of Medicine; KU Leuven, Leuven, Belgium.

ORCID-Profile: Louise Medaer, Koenraad Veys, Rik Gijsbers

Zitieren

APA

Medaer, L., Veys, K., & Gijsbers, R. (2024). Current Status and Prospects of Viral Vector-Based Gene Therapy to Treat Kidney Diseases. Human Gene Therapy, 35(5-6), 139-150. https://doi.org/10.1089/hum.2023.184

Vancouver

Medaer L, Veys K, Gijsbers R. Current Status and Prospects of Viral Vector-Based Gene Therapy to Treat Kidney Diseases. Human Gene Therapy. 2024;35(5-6):139-150. doi:10.1089/hum.2023.184

BibTeX
@article{Medaer2024,
  author = {Medaer, Louise and Veys, Koenraad and Gijsbers, Rik},
  title = {Current Status and Prospects of Viral Vector-Based Gene Therapy to Treat Kidney Diseases},
  journal = {Human Gene Therapy},
  year = {2024},
  volume = {35},
  number = {5-6},
  pages = {139--150},
  doi = {10.1089/hum.2023.184}
}
Kostenlos starten →